Short Interest in ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) Expands By 114.2%

ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) was the target of a large growth in short interest in the month of April. As of April 15th, there was short interest totalling 250,200 shares, a growth of 114.2% from the March 31st total of 116,800 shares. Approximately 1.5% of the company’s stock are short sold. Based on an average daily volume of 1,170,000 shares, the short-interest ratio is currently 0.2 days.

ASLAN Pharmaceuticals Trading Down 7.3 %

Shares of NASDAQ ASLN traded down $0.03 during trading hours on Friday, hitting $0.42. 645,378 shares of the stock were exchanged, compared to its average volume of 869,845. ASLAN Pharmaceuticals has a 12 month low of $0.39 and a 12 month high of $4.69. The firm has a fifty day moving average price of $0.60 and a 200-day moving average price of $0.72.

ASLAN Pharmaceuticals (NASDAQ:ASLN) last issued its quarterly earnings results on Friday, April 12th. The company reported ($0.78) earnings per share (EPS) for the quarter. As a group, sell-side analysts forecast that ASLAN Pharmaceuticals will post -2.68 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ASLN has been the topic of several research reports. HC Wainwright reissued a “buy” rating and set a $9.00 price objective on shares of ASLAN Pharmaceuticals in a report on Tuesday. Piper Sandler reissued an “overweight” rating and issued a $10.00 price target (down from $15.00) on shares of ASLAN Pharmaceuticals in a research report on Wednesday, March 13th.

ASLAN Pharmaceuticals Company Profile

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1 subunit which is being developed for the treatment of atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune diseases.